Psychiatric Comorbidities in Parkinson’s Disease: A Moroccan Perspective on Anxiety and Depression
Open Access
Abstract
Background/Objectives: An individual’s quality of life is greatly impacted by the motor and non-motor symptoms of Parkinson’s disease (PD), which include anxiety and depression. Using the Hospital Anxiety and Depression Scale (HADS), this study sought to determine the prevalence of anxiety and depression in Moroccan patients with Parkinson’s disease (PD) and investigate any possible associations with clinical characteristics and pharmacological treatment. Methods: The HADS was used to assess 100 PD patients in total. Clinical and demographic information, including prescription drug use, was gathered. The relationships between HADS scores and clinical factors were evaluated using Pearson’s correlation. Results: According to the HADS assessment, 20% of respondents had no anxiety symptoms, 17% had borderline symptoms, and 63% of patients reported definite anxiety symptoms. Of those with depression, 24% showed no symptoms, 14% were borderline, and 62% were certain. The average HADS-A and HADS-D scores were 2.34 and 2.43, respectively. L-DOPA alone was used to treat half of the patients, while combinations of Trivastal, Sifrol, anticholinergics, or antidepressants were given to the other half. There were no discernible correlations between HADS scores and clinical or demographic traits. Conclusions: The HADS is a useful instrument for assessing anxiety and depression in PD patients. Regardless of the method of treatment or stage of the disease, psychiatric symptoms are prevalent. For PD patients to benefit from early interventions and achieve an improved quality of life, routine screening is crucial.Keywords
This publication has 24 references indexed in Scilit:
- Anticholinergics May Carry Significant Cognitive and Gait Burden in Parkinson's DiseaseMovement Disorders Clinical Practice, 2020
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine reviewMovement Disorders, 2019
- The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's diseaseMovement Disorders, 2011
- Anxiety disorders in Parkinson's disease: Prevalence and risk factorsMovement Disorders, 2010
- Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s diseaseJournal of Neurology, 2010
- The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's diseaseMovement Disorders, 2009
- Quality of life in Parkinson's disease: The relative importance of the symptomsMovement Disorders, 2008
- A systematic review of prevalence studies of depression in Parkinson's diseaseMovement Disorders, 2008
- Evaluation of anxiety in Parkinson’s disease with some commonly used rating scalesNeurological Sciences, 2007
- Plasma HVA and anxiety in patients with panic disorderBiological Psychiatry, 1986